Evidence map›Paper›PMID 28151949›Full record

ArticlePloS one2017

Identification of small molecules that disrupt vacuolar function in the pathogen Candida albicans.

Helene Tournu, Jennifer Carroll, Brian Latimer, Ana-Maria Dragoi, Samantha Dykes, James Cardelli, Tracy L Peters, Karen E Eberle, Glen E Palmer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Using CMAC Staining for Vacuole Characterization in Yeast.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. In Vitro Incorporation ofPathogens (Basel, Switzerland) · 2020
    Article
  8. Repurposing of Ribavirin as an Adjunct Therapy against InvasiveAntimicrobial agents and chemotherapy · 2019
    Article
  9. mSphere
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Helene TournuDepartment of Clinical Pharmacy, Division of Clinical and Experimental Therapeutics, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, United States of America.
Jennifer CarrollDepartment of Medicine, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.
Brian LatimerDepartment of Medicine, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.
Ana-Maria DragoiDepartment of Medicine, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.
Samantha DykesDepartment of Medicine, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.
James CardelliDepartment of Medicine, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America.
Tracy L PetersDepartment of Clinical Pharmacy, Division of Clinical and Experimental Therapeutics, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, United States of America.
Karen E EberleDepartment of Microbiology, Immunology and Parasitology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Glen E PalmerDepartment of Clinical Pharmacy, Division of Clinical and Experimental Therapeutics, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, United States of America.
Louisiana State University Health Sciences Center Shreveport · USUniversity of Tennessee Health Science Center · USLouisiana State University Health Sciences Center New Orleans · US

Funding

Molecular and chemical validation of the vacuole as a new antifungal targetR01AI099080 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI PALMER, GLEN · 2014 to 2018
$1.9M
A New Class of Broad Spectrum Antifungal AgentsR21AI097664 · NIAID · LSU HEALTH SCIENCES CENTER · PI PALMER, GLEN · 2012 to 2013
$391k
NIAID NIH HHS R01 AI099080NIAID NIH HHS R21 AI097664
6 · The paper itself

Abstract

The fungal vacuole is a large acidified organelle that performs a variety of cellular functions. At least a sub-set of these functions are crucial for pathogenic species of fungi, such as Candida albicans, to survive within and invade mammalian tissue as mutants with severe defects in vacuolar biogenesis are avirulent. We therefore sought to identify chemical probes that disrupt the normal function and/or integrity of the fungal vacuole to provide tools for the functional analysis of this organelle as well as potential experimental therapeutics. A convenient indicator of vacuolar integrity based upon the intracellular accumulation of an endogenously produced pigment was adapted to identify Vacuole Disrupting chemical Agents (VDAs). Several chemical libraries were screened and a set of 29 compounds demonstrated to reproducibly cause loss of pigmentation, including 9 azole antifungals, a statin and 3 NSAIDs. Quantitative analysis of vacuolar morphology revealed that (excluding the azoles) a sub-set of 14 VDAs significantly alter vacuolar number, size and/or shape. Many C. albicans mutants with impaired vacuolar function are deficient in the formation of hyphal elements, a process essential for its pathogenicity. Accordingly, all 14 VDAs negatively impact C. albicans hyphal morphogenesis. Fungal selectivity was observed for approximately half of the VDA compounds identified, since they did not alter the morphology of the equivalent mammalian organelle, the lysosome. Collectively, these compounds comprise of a new collection of chemical probes that directly or indirectly perturb normal vacuolar function in C. albicans.

Indexed as

Antifungal AgentsCandida albicansCell LineColoring AgentsCoumarinsHumansMicrobial Sensitivity TestsMutationPigmentationPigments, BiologicalVacuoles7-amino-4-chloromethylcoumarinAntifungal AgentsColoring AgentsCoumarinsPigments, Biological

Identifiers

PMID28151949
PMCPMC5289544
OpenAlexW2585985039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.